Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xembify in Primary Immunodeficiency
NCT02806986Phase 3Completed
- Sponsor
- Grifols
- Start
- Jun 2016
- Primary completion
- May 2019
- Modality
- Biologic
- Countries
- 9
01
Overview
A Phase 3 trial of immune globulin subcutaneous, human-klhw in primary immunodeficiency (PI), sponsored by Grifols. Started Jun 2016; status: completed.
02
Drugs
immune globulin subcutaneous, human-klhw
03
Conditions
primary immunodeficiency (PI)
Beyond the preview
Go deeper on NCT02806986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02806986.